Notice of NCI's participation on PA-17-461 "Symptoms Cluster Characterization in Chronic Conditions (R21)"

Notice Number: NOT-CA-17-082

Key Dates
Release Date: September 1, 2017

Related Announcements
PA-17-461

Issued by
National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Cancer Institute (NCI) is participating is participating in PA-17-461, "Symptom Cluster Characterization in Chronic Conditions (R21)."

The following changes have been made to reflect NCI's participation in this FOA:

Part 1. Overview Information

Components of Participating Organizations

National Institute of Nursing Research (NINR)
National Cancer Institute (NCI)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.361, 93.393

Part 2. Section I. Funding Opportunity Description

[This section is appended with following statement of NCI's interests.]

In addition to research areas listed in the Funding Opportunity Description, NCI is interested in applications that address the following scientific gaps:

  • Statistical methods used to determine the presence of cancer- and treatment-related clusters;
  • Types of symptoms and dimensions of symptoms used to determine clusters;
  • Stability of symptom clusters over time; and
  • Determining underlying mechanisms of symptom clusters that are site-specific versus treatment-specific, and symptom clusters that are independent of treatment and disease variables.

Section VII. Agency Contacts

The following contacts have been added:

Scientific/Research Contacts

Ann O'Mara, Ph.D., R.N., F.A.A.N.
National Cancer Institute (NCI)
Telephone: 240-276-7050
Email: [email protected]

Financial/Grants Management Contact(s)

Sean Hine
National Cancer Institute (NCI)
Telephone: 240-276-6291
Email: [email protected]

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Ann O'Mara, Ph.D., R.N., F.A.A.N.
National Cancer Institute (NCI)
Telephone: 240-276-7050
Email: [email protected]